Synaffix - About the company
Synaffix is an acquired company based in Nijmegen (Netherlands), founded in 2010. It operates as an Antibody drug conjugate technology platform. Synaffix has raised an undisclosed amount in funding. The company has 3278 active competitors, including 1126 funded and 777 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Synaffix is developing antibody-drug conjugate (ADC) technology platform. Its ADC technology, GlycoConnect, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with their payload-enhancing linker technology, HydraSpace, and BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability. The company is planning to initiate clinical trials for various cancers.
- Website
- synaffix.com
- Social
- Email ID
- *****@synaffix.com
Key Metrics
Founded Year
2010
Location
Nijmegen, Netherlands
Stage
Acquired
Latest Funding Round
Ranked
388th among 3278 active competitors
Employee Count
61 as on Mar 31, 2026
Similar Companies
Exit Details
Acquired by Lonza (Jun 01, 2023)
Synaffix's acquisition details
Click here to take a look at Synaffix's acquisition in detail
Sign up to download Synaffix's company profile
Synaffix's funding and investors
Synaffix has raised funding over 1 round. Its latest funding round was a Series A round on Feb 18, 2014 for $*****. 4 investors participated in its latest round. Synaffix has 5 institutional investors.
Here is the list of recent funding rounds of Synaffix:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 18, 2014 | 8840536 | Series A | 6942586 | 5882276 | 9560926 | 9145858 |
Access funding benchmarks and valuations. Sign up today!View details of Synaffix's funding rounds and investors
Synaffix's founders and board of directors
Founder? Claim ProfileSynaffix's employee count trend
Synaffix has 61 employees as of Mar 26. Here is Synaffix's employee count trend over the years:
Uncover Synaffix's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Synaffix's Competitors and alternates
Top competitors of Synaffix include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Synaffix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
388th | Synaffix 2010, Nijmegen (Netherlands), Acquired | Antibody drug conjugate technology platform | - | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Synaffix's competitors? Click here to see the top ones
Synaffix's Investments and acquisitions
Synaffix has made no investments or acquisitions yet.
News related to Synaffix
Filter this listMedia has covered Synaffix for a total of 4 events in the last 1 year, 2 of them have been about company updates.
•
•
Helmet Security Secures Agentic AI Communications with $9M FundingCIO Influence•Dec 04, 2025•Synaffix, GitHub, SYN Ventures, and 1 other
•
NetFoundry Secures Cisco Investments as Strategic Investor in Series A RoundPR Newswire•Nov 24, 2025•Synaffix, NetFoundry, Cisco Investments, SYN Ventures
•
•
•
Synaffix secures ADC deals with Boehringer and Mitsubishi TanabePharmaceutical Technology•Jan 10, 2025•Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe Pharma
•
Elevation lifts HER3 ADC toward clinic with $368M Synaffix dealFierce Biotech•Dec 12, 2024•Elevation Oncology, Synaffix
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Synaffix
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
